Dr Li Zhang is Professor of Medical Oncology, Director of Phase I Unit of Sun Yat-Sen University Cancer Centre (SYSUCC), Deputy Director of Lung Cancer Research Centre of SYSU. He is also the member of ASCO, CSCO, ESMO, IASLC, MASCC and Member of communication committee of IASLC. Professor Zhang has published more than 200 clinical papers in top-tier journals like: Lancet, Lancet Oncology, Lancet Respiratory Medicine, Journal of Clinical Oncology, JAMA Oncology, Nature Communications, Annals of Oncology, JTO, JNCI. He also presented abstracts to many major congresses like ASCO, WCLC, ESMO, MASCC meetings.  He is an editorial board member of Clinical Lung Cancer, Chinese Journal of Clinical Oncology, and Cancer Communications. At present, he is a senior consultant to the Centre of Drug Evaluation, Chinese Food and Drug Administration (CFDA) and had formerly drafted the CFDA Guidance for Industry: Clinical Trial for the Approval of Cancer Drugs and Biologics (second version, 2006).

For information on Professor Li's laboratory, click here and select: Patient care improvement.

Dr Zhang received his master of clinical oncology degree from SYSU and was board certified as a physician in medical oncology. He has completed training as a visiting fellow at the MD Anderson Cancer Centre, Houston; Fox Chase Cancer Centre, Philadelphia, USA and Institut Gustave Roussy, Paris, France.

Selected publications

1. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.  Li Zhang, Y Huang, S Hong, Y Yang, G Yu, J Jia, P Peng, X Wu, Q Lin, X Xi, J Peng, M Xu, D Chen, X Lu, R Wang, X Cao, X Chen, Z Lin, J Xiong, Q Lin, C Xie, Z Li, J Pan, J Li, S Wu, Y Lian, Q Yang, C Zhao The Lancet 2016

2. Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804). Li Zhang, S Ma, X Song, B Han, Y Cheng, C Huang, S Yang, X Liu, Y Liu, S Lu, J Wang, S Zhang, C Zhou, X Zhang, N Hayashi, M Wang.  Lancet Oncology 2012

3. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. W Fang, Y Yang, Y Ma, S Hong, L Lin, X He, J Xiong, P Li, H Zhao, Y Huang, Y Zhang, L Chen, N Zhou, Y Zhao, X Hou, Q Yang, Li Zhang  Lancet Oncology 2018

4. Challenges in anticancer drug R&D in China.  S Zhao, C Lv, J Gong, W Fang, X Hu, Y Ba, X Chen, Z Yang, L Shen, Li Zhang Lancet Oncology 2019

5. ALESIA: a randomised phase 3 study of alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. C Zhou, S Kim, T Reungwetwattana, J Zhou, Y Zhang, J He, J Yang, Y Cheng, S Lee, L Bu, T Xu, L Yang, C Wang, T Liu, P N. Morcos, Y Lu, Li Zhang The Lancet Respiratory Medicine 2019

6. Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.     Y Yang, J Zhou, J Zhou, J Feng, W Zhuang, J Chen, J Zhao, W Zhong, Y Zhao, Y Zhang, Y Song, Y Hu, Z Yu, Y Gong, Y Chen, F Ye, S Zhang, L Cao, Y Fan, G Wu, Y Guo, C Zhou, K Ma, J Fang, W Feng, Y Liu, Z Zheng, G Li, N Wu, W Song, X Liu, S Zhao, L Ding, L Mao, G Selvaggi, X Yuan, Y Fu, T Wang, S Xiao, Li Zhang  The Lancet Respiratory Medicine 2020

7. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: preliminary results.  Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, Wu SX.  Journal of Clinical Oncology 2005

8. Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non–Small Cell Lung Cancer. S Hong, F Gao, S Fu, Y Wang, W Fang, Y Huang, Li Zhang. JAMA Oncology 2018

9. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Hong S, Liu D, Luo S, Fang W, Zhan J, Fu S, Zhang Y, Wu X, Zhou H, Chen X, Chen G, Zhang Z, Zheng Q, Li X, Chen J, Liu X, Lei M, Ye C, Wang J, Yang H, Xu X, Zhu S, Yang Y, Zhao Y, Zhou N, Zhao H, Huang Y, Zhang L, Wu K, Zhang Li. Nature Communications 2019

10. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.  Y Zhang, Y Yang, Z Zhang, W Fang, S Kang, Y Luo, J Sheng, J Zhan, S Hong, Y Huang, N Zhou, H Zhao, Li Zhang  Journal of The National Cancer Institute 2017

11. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer. W Fang, Y Ma, J Yin, S Hong, H Zhou, A Wang, F Wang, H Bao, X Wu, Y Yang, Y Huang, H Zhao, Y Shao, Li Zhang Clinical Cancer Research 2019

Last updated: April 2020 by International Office, Sun Yat-sen University Cancer Center